BioCryst Pharmaceuticals, Inc. (BCRX) Stock Price & How to Invest
Last updated November 2026
Short answer
BCRX is BioCryst Pharmaceuticals, a commercial-stage rare-disease biotech whose story now rides almost entirely on ORLADEYO, its oral once-daily pill for hereditary angioedema (HAE). It is a single-product growth company transitioning toward profitability while spending heavily to defend and extend its HAE franchise, so anyone weighing it is really taking a view on ORLADEYO durability plus the Astria-acquired injectable navenibart. As of November 20, 2026 the shares closed at $7.28, down about 3% year to date and about 26% over three months, even after a third quarter that beat estimates and guidance that management now expects to land at the upper end of its range.
BCRX stock price
As of 2026-11-20, BioCryst Pharmaceuticals, Inc. (BCRX) last closed at $7.22, up 3.6% over the past year. Over the past 52 weeks it has traded between $6.24 and $11.11.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or BioCryst Pharmaceuticals, Inc.'s investor relations page. Walnut is informational, not investment advice.
BCRX key stats
At $7.22 on November 20, 2026, BioCryst Pharmaceuticals, Inc. (BCRX) has a market cap of $1.9B.
- Market cap
- $1.9B
- P/E (forward)
- 8.4
- Beta
- 0.51
Market cap, P/E and yield are measured at the $7.22 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with BioCryst Pharmaceuticals, Inc. (BCRX)?
The last two weeks for BioCryst Pharmaceuticals, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- BCRX closed at $7.22 on November 20, 2026, down 5.1% over the past five trading days (from $7.61).
BioCryst Pharmaceuticals, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
BioCryst Pharmaceuticals, Inc. (BCRX) latest quarter
BioCryst Pharmaceuticals reported revenue of $180 million for Q3 2026, up 13% from a year earlier (BioCryst Pharmaceuticals, Nov 4, 2026).
Source: BioCryst Q3 2026 financial results, Nov 4, 2026. Full earnings breakdown
What does BioCryst Pharmaceuticals, Inc. (BCRX) do?
BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases, with a near-total focus on hereditary angioedema (HAE), a genetic disorder that causes unpredictable and sometimes life-threatening swelling attacks. Its lead product is ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor approved to prevent HAE attacks, which competes against injectable and infused prophylaxis therapies. The company also markets RAPIVAB (peramivir) for influenza and, through its January 2026 acquisition of Astria Therapeutics, added navenibart (formerly STAR-0215), a long-acting injectable antibody in Phase 3 for HAE prophylaxis, plus an early-stage ocular program (avoralstat).
The investment picture is a concentrated, single-franchise growth story approaching an inflection. ORLADEYO net revenue reached roughly $601 million in 2025 (up about 37 percent) and management guides to roughly $625 to $645 million for 2026, and BioCryst has been converting that growth into non-GAAP operating profit even as headline GAAP results were dominated by a large one-time non-cash charge tied to the Astria deal. The key tensions are ORLADEYO's peak-sales ceiling, an increasingly crowded HAE market, and the debt and dilution taken on to fund navenibart, which is not expected to be filed until around the end of 2027.
The second quarter of 2026 complicated the growth story. Total revenue was about $218 million, up about 34% year over year, but that included about $55.7 million recognized from a European licensing deal for navenibart that the company treats as non-recurring, and ORLADEYO net revenue itself rose only about 1% on a reported basis. The third quarter, reported November 4, 2026, was steadier: total revenue was about $180 million against a consensus near $166 million, GAAP net income was about $38 million ($0.14 per diluted share), and adjusted EPS of $0.27 beat the $0.12 estimate. BioCryst said it increased its 2026 revenue guidance, and on the earnings call management said it expects revenue near the upper end of its $625 million to $645 million range, with more than 1,600 U.S. patients on ORLADEYO and an estimated 22% to 23% share of treated HAE patients. In August 2026 Japan approved ORLADEYO for children aged 2 to 12, and BioCryst has since launched a pellet formulation for children aged 2 to 11 in addition to approval of a 150-milligram pellet for patients 12 and older. Phase 3 navenibart data are now expected in the third quarter of 2027. The stock has not followed the results: at $7.28 on November 20, 2026 it is down about 26% over three months and about 3% year to date, up about 4% over one year, for a market value near $1.9 billion and about 8.5x forward earnings.
What's driving BioCryst Pharmaceuticals, Inc. (BCRX)?
1. ORLADEYO revenue growth and operating leverage
ORLADEYO is the engine, growing from about $601 million in 2025 toward guided 2026 revenue of roughly $625 to $645 million, which management said after Q3 2026 it expects to reach at the upper end, as the only oral once-daily HAE prophylaxis. As a high-margin small molecule with a largely built-out commercial base, incremental sales drop toward the bottom line, and trailing operating margin is near 49% on Yahoo Finance's measure. Continued patient adds and international expansion are the swing factor: reported ORLADEYO growth slowed from about 11% in Q1 2026 to about 1% in Q2, and management now cites more than 1,600 U.S. patients on therapy, more than 60 new prescribers a quarter and a share of treated HAE patients of about 22% to 23% that it expects to rise into the mid-20s.
2. Navenibart and the Astria pipeline bet
The roughly $700 million enterprise-value Astria acquisition brought navenibart, a long-acting injectable plasma kallikrein antibody in Phase 3 for HAE with potential dosing as infrequent as every three or six months. Phase 3 data are expected in the third quarter of 2027, and management has said a launch could use the existing 40-person sales force. If it reads out well and files around the end of 2027, it could extend BioCryst's HAE leadership beyond ORLADEYO's oral niche. BioCryst has already begun monetizing it, recognizing about $55.7 million in Q2 2026 from a European licensing deal for navenibart. It is also the largest single reason for the added debt, share issuance, and the big one-time acquired-IPR&D charge.
3. Path to sustained GAAP profitability and self-funding
BioCryst has been pivoting toward a leaner model, ending internal discovery work and leaning on partnerships to cut cash burn. Management guides 2026 operating expenses to about $415 million to $425 million and expects them to fall further in 2027, with the goal of funding navenibart's late-stage program largely from ORLADEYO cash flow rather than repeated capital raises. Reaching durable GAAP profitability would materially change how the market values the franchise; GAAP net income was about $78 million in Q2 2026 (helped by the one-time navenibart licensing revenue) and about $38 million in Q3, and trailing free cash flow was about $301 million. In October 2026 the company formed a scientific advisory board to support a model built on acquiring and licensing outside rare-disease assets, and management says it is searching for additional clinical-stage assets.
4. International and label expansion of the HAE franchise
Beyond the core U.S. business, BioCryst continues to widen ORLADEYO's geographic footprint and pursue additional data (including pediatric and long-term durability evidence) to defend share. In August 2026 Japan's health ministry approved ORLADEYO for children aged 2 to 12 with HAE, the first oral prophylactic for pediatric HAE patients there, and BioCryst has launched a pellet formulation for children aged 2 to 11, with early uptake ahead of the company's expectations. In November 2026 it presented real-world evidence at the ACAAI annual meeting showing fewer angioedema-related medical visits after patients switched to ORLADEYO. Broader reimbursement and new markets add incremental revenue without proportionate cost, supporting the guided revenue trajectory.
What are the risks to BioCryst Pharmaceuticals, Inc. (BCRX)?
BioCryst is a concentrated single-franchise story: the large majority of revenue comes from ORLADEYO, so any competitive share loss, pricing pressure, or safety signal would hit hard; reported ORLADEYO growth of only about 1% in Q2 2026 shows how quickly the trajectory can flatten. The HAE prophylaxis market is crowding fast, with Takeda's Takhzyro, CSL's Andembry, and Ionis's Dawnzera (donidalorsen) all competing for the same patients on convenience and dosing frequency. The Astria acquisition added debt (including a Blackstone financing facility; total debt was about $828 million against about $375 million of cash as of September 30, 2026) and share dilution, and navenibart still carries clinical and regulatory risk with Phase 3 data expected in the third quarter of 2027 and a filing only around the end of 2027. GAAP results have been distorted by large non-cash charges, and the company has a history of operating losses, so profitability at the GAAP level is not yet proven. As a biotech, it remains sensitive to trial outcomes, regulatory decisions, and financing conditions. The share price has also fallen about 26% in three months despite beats, and Wedbush trimmed its target to $17 from $18 on November 4, 2026, so sentiment can move independently of reported results.
What is the BioCryst Pharmaceuticals, Inc. (BCRX) forecast?
11 analysts publish price targets on BCRX, averaging $20.45 as of November 2026, or +183.2% against the $7.22 share price on November 20, 2026. The published targets run from $11.00 to $32.00, a wide spread, and the ratings split 9 buy, 2 hold, 0 sell. Over the last six months there have been 3 raises and 5 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full BCRX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is BCRX a buy or a sell?
We give no verdict on BioCryst Pharmaceuticals, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. ORLADEYO revenue growth and operating leverage. ORLADEYO is the engine, growing from about $601 million in 2025 toward guided 2026 revenue of roughly $625 to $645 million, which management said after Q3 2026 it expects to reach at the upper end, as the only oral once-daily HAE prophylaxis. The most optimistic published target, $32.00, assumes this works close to its best case.
The case against. BioCryst is a concentrated single-franchise story: the large majority of revenue comes from ORLADEYO, so any competitive share loss, pricing pressure, or safety signal would hit hard; reported ORLADEYO growth of only about 1% in Q2 2026 shows how quickly the trajectory can flatten. The most pessimistic target, $11.00, is roughly what BCRX is worth if this bites instead.
Read the full bull and bear case on BCRX, including what would have to change to break either one. Walnut is not an investment adviser.
Has BioCryst Pharmaceuticals, Inc. (BCRX) split its stock?
No. BioCryst Pharmaceuticals, Inc. (BCRX) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is BioCryst Pharmaceuticals, Inc. (BCRX) valued?
Market cap, P/E and dividend yield at today's price are in the BCRX key stats above. The business figures below come from BioCryst Pharmaceuticals, Inc.'s reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$962M (includes one-time licensing revenue)
- Q3 2026 total revenue: ~$180M (up ~13% YoY; ~$166M estimate)
- Q3 2026 EPS: Adjusted $0.27 vs $0.12 estimate; GAAP $0.14 diluted
- 2026 revenue guidance: ~$625M to $645M, upper end expected
- Net income (TTM): ~-$360M loss (Astria IPR&D charge in Q1 2026)
- Cash / debt: ~$375M cash; ~$828M debt
As of November 2026: BioCryst trades on the strength and durability of its ORLADEYO franchise rather than on trailing GAAP earnings, which still show a net loss of about $360 million because of the roughly $698 million one-time acquired-IPR&D charge from the Astria deal in Q1 2026. Trailing revenue near $962 million is inflated by one-time licensing items, so the guided $625 to $645 million of 2026 revenue is the cleaner base, and analysts expect about $736 million in 2027. At $7.28 the stock trades near 8.5x forward earnings and about 5x EV/EBITDA, while the 11 analysts tracked by Yahoo Finance carry a mean target near $20.
Who competes with BioCryst Pharmaceuticals, Inc. (BCRX)?
Injectable and infused HAE prophylaxis leaders
Takeda's Takhzyro (lanadelumab) and CSL Behring's Haegarda and newer Andembry are the entrenched subcutaneous or infused prophylaxis therapies BioCryst set out to disrupt with an oral pill. Takhzyro alone has been a roughly billion-dollar-plus franchise, so these are the scale competitors for the same patient pool.
Next-generation and RNA-targeted HAE entrants
Ionis's Dawnzera (donidalorsen) is an RNA-targeted subcutaneous prophylaxis with infrequent dosing, and navenibart (which BioCryst itself acquired) represents the long-acting antibody wave. These newer mechanisms and dosing schedules are the main threat to ORLADEYO's convenience advantage over time.
Broader rare-disease and specialty pharma
As a focused rare-disease commercial-stage biotech, BioCryst competes for investor capital and commercial talent with other single- or few-product specialty pharmas. Its profile (fast-growing lead product, late-stage pipeline bet, path toward profitability) puts it in the same bucket investors compare against similar mid-cap rare-disease names.
What stocks are similar to BioCryst Pharmaceuticals, Inc. (BCRX)?
Other names that sit close to BCRX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in BioCryst Pharmaceuticals, Inc. (BCRX)
There are three common ways to get BCRX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so BCRX sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where BCRX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on BioCryst Pharmaceuticals, Inc. (BCRX)
BioCryst is a focused HAE pharma with a fast-growing oral franchise and a big pipeline bet, so the picture hinges on ORLADEYO staying dominant against a widening field of rival prophylaxis drugs.
More on BioCryst Pharmaceuticals, Inc. (BCRX)
Whether BCRX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BCRX a buy or a sell?, and where the stock could go from here in the BCRX stock forecast.
For income investors, whether BCRX pays a dividend and how the payout looks is covered in does BCRX pay a dividend? And to weigh BCRX against a peer, read the full side-by-side comparisons: BCRX vs HAE and BCRX vs CSL.
Wondering how BCRX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about BioCryst Pharmaceuticals, Inc.
Ask Walnut's AI anything about BCRX and see how it fits what you own.
FAQ
What does BioCryst Pharmaceuticals (BCRX) do?
+
BioCryst is a commercial-stage biotech focused on rare diseases, especially hereditary angioedema (HAE). Its main product is ORLADEYO, an oral once-daily pill that prevents HAE swelling attacks. It also markets RAPIVAB for influenza and is developing the injectable navenibart for HAE.
What is ORLADEYO and why does it matter so much to BCRX?
+
ORLADEYO (berotralstat) is the first oral, once-daily plasma kallikrein inhibitor approved to prevent HAE attacks, competing against injectable and infused therapies. It accounts for the large majority of BioCryst's revenue, so the company's results and outlook track closely with ORLADEYO sales.
How fast is ORLADEYO growing?
+
ORLADEYO net revenue reached roughly $601 million in 2025, up about 37 percent, and management guides to roughly $625 million to $645 million for 2026, which it said after third-quarter results it expects to reach at the upper end. First-quarter 2026 ORLADEYO revenue was about $148 million, up roughly 11 percent year over year on a reported basis, but growth slowed to about 1 percent in the second quarter. More than 1,600 U.S. patients are now on therapy, according to management.
Why did BioCryst acquire Astria Therapeutics?
+
BioCryst acquired Astria in January 2026 (around $700 million enterprise value) mainly to obtain navenibart, a long-acting injectable antibody in Phase 3 for HAE prophylaxis. The goal is to extend its HAE leadership beyond ORLADEYO's oral niche, though the deal added debt and dilution.
Is BioCryst profitable?
+
BioCryst reported GAAP net income of about $78 million in Q2 2026 (helped by about $55.7 million of one-time licensing revenue) and about $38 million in Q3 2026, but trailing twelve-month GAAP results still show a net loss of about $360 million, driven by a roughly $698 million one-time non-cash charge from the Astria acquisition in the first quarter. Sustained GAAP profitability is a stated goal but not yet proven across a full year.
Who are BioCryst's main competitors?
+
In HAE prophylaxis it competes with Takeda's Takhzyro, CSL Behring's Haegarda and Andembry, and Ionis's Dawnzera (donidalorsen). These include entrenched injectable leaders and newer RNA-targeted and long-acting entrants offering different dosing convenience.
What are the biggest risks for BCRX?
+
The main risks are heavy reliance on a single product (ORLADEYO), a crowding HAE market, about $828 million of debt and the dilution from the Astria deal, and clinical and regulatory risk on navenibart, whose Phase 3 data are expected in the third quarter of 2027 and which is not expected to be filed until around the end of 2027. As a biotech it is also sensitive to trial and financing outcomes.
How can someone invest in or research BCRX?
+
BCRX trades on the Nasdaq, so it can be bought through a standard brokerage account like any US-listed stock. Investors typically research its ORLADEYO revenue trend, competitive share in HAE, cash and debt position, and navenibart progress. Walnut is not an investment adviser, and this is descriptive information, not a recommendation.
How did BioCryst do in its latest quarter?
+
In the third quarter of 2026, reported November 4, BioCryst posted total revenue of about $180 million, up about 13% year over year and ahead of a consensus near $166 million. GAAP net income was about $38 million ($0.14 per diluted share) and adjusted EPS of $0.27 beat the $0.12 estimate. The company raised its 2026 revenue guidance and said it expects to land near the upper end of $625 million to $645 million.
How has BCRX stock performed in 2026?
+
As of the November 20, 2026 close of $7.28, BCRX was down about 3% year to date, about 26% over three months and about 5% over one month, and up about 4% over one year, within a 52-week range of roughly $6.23 to $11.22. It trades near 8.5x forward earnings, and the 11 analysts tracked by Yahoo Finance have a mean target near $20.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with BioCryst Pharmaceuticals, Inc.'s investor relations page or your broker before making investment decisions.